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Abstract
Background: Observational studies have investigated the association of risk factors with breast cancer prognosis.
However, the results have been conflicting and it has been challenging to establish causality due to potential
residual confounding. Using a Mendelian randomisation (MR) approach, we aimed to examine the potential causal
association between breast cancer-specific survival and nine established risk factors for breast cancer: alcohol
consumption, body mass index, height, physical activity, mammographic density, age at menarche or menopause,
smoking, and type 2 diabetes mellitus (T2DM).
Methods: We conducted a two-sample MR analysis on data from the Breast Cancer Association Consortium (BCAC)
and risk factor summary estimates from the GWAS Catalog. The BCAC data included 86,627 female patients of
European ancestry with 7054 breast cancer-specific deaths during 15 years of follow-up. Of these, 59,378 were
estrogen receptor (ER)-positive and 13,692 were ER-negative breast cancer patients. For the significant association,
we used sensitivity analyses and a multivariable MR model. All risk factor associations were also examined in a
model adjusted by other prognostic factors.
Results: Increased genetic liability to T2DM was significantly associated with worse breast cancer-specific survival
(hazard ratio [HR] = 1.10, 95% confidence interval [CI] = 1.03–1.17, P value [P] = 0.003). There were no significant
associations after multiple testing correction for any of the risk factors in the ER-status subtypes. For the reported
significant association with T2DM, the sensitivity analyses did not show evidence for violation of the MR
assumptions nor that the association was due to increased BMI. The association remained significant when
adjusting by other prognostic factors.
Conclusions: This extensive MR analysis suggests that T2DM may be causally associated with worse breast cancer-
specific survival and therefore that treating T2DM may improve prognosis.
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Background
Breast cancer is a heterogeneous disease with a broad
variation in prognosis [1]. Providing a precise prognosti-
cation for breast cancer patients is important in order to
inform them accurately about the course of the disease
and to allocate them to the right treatment [2]. To date,
most commonly used prognostic factors relate to
tumour characteristics and the extent of the disease at
the time of diagnosis [2]. Many observational studies
have evaluated the association of breast cancer risk and
survival with other patient characteristics and lifestyle-
related risk factors [3–5]. However, due to their observa-
tional nature, it is difficult for these studies to establish
causation. Understanding whether or not the association
between breast cancer survival and risk factors is causal
might influence strategies to improve survival in breast
cancer patients. In theory, randomised control trials
(RCTs) provide a reliable method to evaluate the causal
relationship between risk factors and survival [6, 7], but
they are often not feasible as they can be prohibitively
expensive, time-consuming, and even unethical. If an
RCT cannot be performed to assess the causal effect be-
tween a risk factor and the outcome of interest, methods
using instrumental variables may be an alternative.
Mendelian randomisation (MR) is a popular analytical
method that uses genetic variants as instrumental vari-
ables (i.e. genetic instruments). This methodology uses a
genetic predictor for the risk factor. Because of the nat-
ural randomisation of alleles during meiosis, this genetic
predictor will be independently distributed across a
population. Theoretically, therefore, this genetic instru-
ment is not affected by potential environmental con-
founding factors or by disease status. MR rests on three
basic assumptions: (1) genetic variants are associated
with the risk factor (relevance assumption), (2) those
genetic variants are not associated with any known or
unknown confounders (independence assumption), and
(3) the genetic variants affect the outcome only through
the risk factor (exclusion restriction assumption) [8].
Using a genetic score that combines multiple variants
explaining a large R-squared of the risk factor can help
reducing the probability of violating the first MR as-
sumption and providing more powerful MR analyses.
The third assumption is also known as independence
from horizontal pleiotropy, which occurs when the
genetic variants influence the outcome by means of
other pathways independently of the risk factor [8].
Several methods and sensitivity tests exist to assess these
assumptions [9].
In this study, we used MR analysis to evaluate the
causal relationships between breast cancer-specific sur-
vival and nine established risk factors for breast cancer:
alcohol consumption, body mass index (BMI), height,
mammographic density, menarche (age at onset),
menopause (age at onset), physical activity, smoking,
and type 2 diabetes mellitus (T2DM). Observational
studies have provided evidence for the potential associ-
ation of these risk factors and breast cancer survival,
sometimes with conflicting results.
A population-based prospective study found that
smoking before or after breast cancer diagnosis is associ-
ated with worse breast cancer survival [10]. Another
meta-analysis of cohort studies concluded that current
smoking is associated with worse breast cancer-specific
survival compared to never smoking in breast cancer pa-
tients [11]. Obesity (BMI of ≥ 30.0) has been associated
with worse breast cancer survival in a meta-analysis and
systematic review [12]. In another review, obesity was as-
sociated with worse breast cancer prognosis for women
of all ages [13]. For T2DM, a retrospective study of
breast cancer patients found that diabetes was independ-
ently associated with poorer breast cancer prognosis
[14]. In a population-based study, breast cancer-specific
mortality was higher among women with diabetes
compared to non-diabetic patients [15]. In relation to
menstrual risk factors, a population-based study showed
that early age at menarche was significantly associated
with poorer survival but age at menopause did not have
a significant impact [16]. The relationship between mam-
mographic density and breast cancer survival has been
studied in several cohort studies, but results have been in-
conclusive [17–19]. For other factors such as physical
activity, the evidence is also not clear: in an RCT with an
8-year follow-up, no significant difference in disease-free
survival was found between an exercise group and a usual
care group [20]. To date, there is no evidence for an
association between height or post-diagnosis alcohol con-
sumption and breast cancer survival [21].
Our hypothesis was that some of these risk factors, for
which there is evidence of an association with breast
cancer survival based on observational data, might have
a causal association with breast cancer-specific survival.
We also aimed to investigate whether we could ob-
serve—or refute—an effect for the risk factors for which
the association is not clear. We therefore performed a
two-sample MR analysis using genetic variants and risk
factor association summary estimates from the GWAS
Catalog [22] and breast cancer survival summary esti-
mates from the Breast Cancer Association Consortium
(BCAC) cohort [23].
Methods
Selection of risk factors
We first considered the full list of breast cancer risk fac-
tors provided on the Cancer Research UK site [33] as of
January 2020 (Additional file 1: Table S1). From this list
of 25 factors, we identified nine factors for which
genome-wide association study (GWAS) data were
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available. Only GWASs that could be directly down-
loaded from GWAS Catalog [22] into TwoSampleMR
[34] R package were considered. If there were multiple
GWAS for one risk factor, we selected the study with
the largest sample size from those that were
predominantly of European ancestry (Table 1). We
considered only genome-wide significant variants (P <
5 × 10−8) to ensure that the association with the risk
factor was robust (first MR assumption). Only single-
nucleotide polymorphisms (SNPs) were considered as
the reference panel did not include other types of
variants. Variants correlated with the most significant
SNPs were removed so that only uncorrelated variants
remained in the analysis (r2 < 0.001). We calculated a
priori power to detect an association at a significant
level of 0.05 for each risk factor using the tool
(https://sb452.shinyapps.io/power) [35]. We used the
number of events (n = 7054) as sample size.
Breast cancer survival and genetic data
The breast cancer survival data was obtained from the
Breast Cancer Association Consortium (BCAC). We
analysed clinic-pathological data (database version 12)
and genotype data from the OncoArray [36] and iCOGS
arrays [37]. The analysis included 86,627 female patients
of European ancestry diagnosed at age > 18 years with in-
vasive breast cancer of any stage. The dataset included
7054 breast cancer-specific deaths. A total of 59,378 pa-
tients (4246 deaths) had ER-positive disease, and 13,692
(1733 deaths) had ER-negative disease. Genotypes for
variants not present on the arrays were imputed using
the Haplotype Reference Consortium [38] as reference
panel. Details about the genotyping, sample quality con-
trol, and imputation procedure have been described pre-
viously [36, 39]. Our analyses were based on SNPs that
were imputed with imputation r2 > 0.7 and had minor al-
lele frequency > 0.01 in at least one of the two datasets
(iCOGS or OncoArray).
Breast cancer survival estimates
We took the SNPs referred to in Table 1 as genetic in-
struments for each of the nine risk factors. For every
SNP, we performed survival analyses to obtain survival
estimates as described previously [23]. The analyses in-
cluded the full OncoArray and iCOGS datasets. Time at
risk was calculated from the date of diagnosis with left
truncation for prevalent cases. Follow-up was right cen-
sored on the date of death, last date known alive if death
did not occur, or at 15 years after diagnosis, whichever
came first [39]. We estimated the association between
the genetic instruments and breast cancer-specific sur-
vival using Cox proportional hazards regression [40].
The models were stratified by study and included the
first two ancestry informative principal components,
based on the genotyping array data as previously de-
scribed, to adjust for population structure [36, 37]. We
analysed the OncoArray and iCOGS datasets separately
and then combined the estimates using fixed-effect
Table 1 Description of the nine risk factors with available genetic data from GWAS




Study reference Sample size Population
Alcohol consumption (drinks per week)† 98 GCST007472 Liu et al. [24] 1,039,210 100%
European
Body mass index (adult, kg/m2) 100 GCST006368 Hoffmann et al. [25] 334,487 81%
European
Height (adult, m) 112 GCST002647 Wood et al. [26] 253,288 100%
European
Mammographic density (dense vs non-
dense area)
5 GCST002667 Lindström et al. [27] 16,015** 100%
European
Menarche (age at onset) 82 GCST002541 Perry et al. [28] 182,413** 100%
European
Menopause (age at onset) 34 GCST005312 Day et al. [29] 69,626** 100%
European
Physical activity (overall physical activity
time)
3 GCST006912 Doherty et al. [30] 91,105 100%
European








*The number of SNPs here may be lower than in the GWAS due to filtering (see the “Methods” section)
**Partial overlap with samples from BCAC
†Defined as the average number of drinks a participant reported drinking each week, aggregated across all types of alcohol
‡This is a binary phenotype. Participants who reported ever being a regular smoker in their life (current or former) were coded “2”, while participants who
reported never being a regular smoker in their life were coded “1”
Escala-Garcia et al. BMC Medicine          (2020) 18:327 Page 3 of 10
meta-analyses [39]. Analyses were carried out for all in-
vasive breast cancer and for estrogen receptor (ER)-posi-
tive and ER-negative disease separately. Additional file 2:
Tables S1-S9 provides the full list of SNPs used and the
corresponding estimates for the per-allele risk factor ef-
fect sizes and the per-allele survival log (hazard ratios).
MR statistical analyses and sensitivity diagnostics
We used the TwoSampleMR [34] R package to perform
the two-sample MR analyses. We obtained the genetic
instruments for the risk factors (MR-Base NHGRI-EBI
GWAS Catalog [22], 29 August 2019 update), harmo-
nised the SNP effects so they corresponded to the same
allele for the risk factor and survival associations, and
performed the sensitivity tests. We estimated the causal
relationships between each of the sets of SNPs for the
nine risk factors and breast cancer-specific survival using
the inverse-variance weighted (IVW) method. We
performed the analyses for all invasive breast cancer,
ER-positive, and ER-negative separately. The association
of BMI with breast cancer-specific survival was
previously evaluated in an earlier, smaller version of the
BCAC dataset (n = 36,210) [41]. In this analysis, we in-
cluded more patients, updated follow-up, and a larger
BMI GWAS genetic instrument. It has been suggested
that the potential negative effect of BMI on survival is
especially relevant in postmenopausal women [12].
Therefore, we also tested whether the BMI associations
differed between pre- (age at diagnosis under 50 years,
n = 27,009 with 2680 breast cancer-specific deaths) and
postmenopausal women (age at diagnosis 50 years or
older, n = 59,617 with 4374 breast cancer-specific
deaths). Inclusion of even a small percentage of a
different ethnic group can affect the interpretation and
validity of the causal estimates [42]. Because the genetic
instrument that we used for BMI had 19% of non-
European participants, we performed an additional
analysis using the BMI European-specific summary esti-
mates from the same GWAS available at the author’s
supplementary material [25] (61 SNPs after filtering,
Additional file 2: Table S10).
IVW assumes that none of the variants exhibit hori-
zontal pleiotropy, which may not be true in practice.
Therefore, we also used the MR-Egger regression
method that allows variants to demonstrate unbalanced
pleiotropic associations. That is, MR-Egger regression
relaxes the requirement of no horizontal pleiotropy pro-
vided that the pleiotropic effects are not proportional to
the effects of the variants on the risk factors of interest
[8, 9]. In comparison to the IWM, the MR-Egger
method’s intercept is not constrained to zero and
provides a statistical test of the extent to which this
intercept differs from zero as a measure of unbalanced
pleiotropic effects.
For the risk factors with a significant association based
on the IVW method (false discovery rate [FDR] < 0.05),
we ran the following sensitivity analyses: heterogeneity
tests, funnel plots, and leave-one-out tests. To assess the
robustness of the results of the IVW method, we applied
other MR methods (simple mode, weighted median, and
weighted mode). We also tested all associations by
performing the analysis using a multivariable model. In
the multivariable model, we used imputed phenotypes
[43] and adjusted for the following known prognostic
factors: age of the patients at diagnosis; tumour size;
node status; distant metastasis status; grade; ER-, proges-
terone receptor, and HER2-status; and (neo) adjuvant
chemotherapy, adjuvant anti-hormone therapy, and ad-
juvant trastuzumab. Because breast cancer survival can
differ on the short or longer term, we also assessed
whether or not the associations would hold for the 5-
year horizon, which is typically used in breast cancer
prognostication [44]. For this analysis, we reduced the
follow-up time from 15 to 10 years (n = 85,470 with 6147
breast cancer-specific deaths) and 5 years (n = 79,183
with 3573 breast cancer-specific deaths). Both in the
multivariable model and the shorter follow-up analyses,
we performed the MR analyses separately for OncoArray
and iCOGS datasets and meta-analysed the results.
Relationships between BMI, T2DM, and breast cancer
survival
To ensure that the effects of BMI and T2DM were inde-
pendent, we identified SNPs that overlapped between
the genetic instruments for these risk factors. Two SNPs,
rs7144011 and rs7903146, were present in both the BMI
and T2DM instrumental variables, and 12 (six pairs)
SNPs were in linkage disequilibrium (LD): rs2972144,
rs4072096, rs1801282, rs1899951, rs2112347, rs2307111,
rs4715210, rs72892910, rs244415, rs889398, rs6059662,
and rs6142096. We removed those 14 SNPs from the
analyses to reduce the likelihood of horizontal plei-
otropy. To further isolate the association of T2DM
alone, we performed a multivariable MR model [45] by
additionally including the genetically predicted BMI
score as a covariate in the analyses of T2DM.
Results
We found a significant association between genetic li-
ability to T2DM and breast cancer-specific survival (P <
0.05, Table 2). For all breast cancers, T2DM was associ-
ated with worse breast cancer-specific survival (hazard
ratio [HR] = 1.10, 95% confidence interval [CI] = 1.04–
1.18, P value [P] = 0.003, FDR = 0.023) (Fig. 1 and
Table 2). T2DM was also associated with worse breast
cancer-specific survival when restricting to ER-positive
cases. The effect in the ER-positive subtype was consist-
ent (HR = 1.09, CI = 1.01–1.18, P = 0.036, FDR = 0.324)
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with the effect in all breast cancers. We did not observe
associations at FDR < 0.05 (Table 2) between survival,
for all breast cancer or by ER-subtype, and any of the
other risk factors: alcohol consumption, BMI, height,
mammographic density, menarche, menopause, physical
activity, and smoking. The estimates we obtained from
the models adjusted by other known prognostic factors
(Additional file 1: Table S2) were comparable to the ini-
tial unadjusted analyses for all risk factors. Under the
current sample size of our study (n = 86,627 and 7054
events), the power to detect a causal association varied
considerably between risk factors (Additional file 1:
Table S3). The estimated power was the largest for age
at menopause and lowest for physical activity.
Genetic association between BMI by menopausal status
and breast cancer-specific survival
We found no association between BMI and breast
cancer-specific survival in any of the analysed subtypes,
nor by menopausal status (P > 0.05): premenopausal
(HR = 1.06, CI = 0.78–1.44, P = 0.710) or postmenopausal
women (HR = 1.02, CI = 0.80–1.30, P = 0.899). The esti-
mate using the European-specific BMI genetic
Table 2 Effect of nine breast cancer risk factors on breast cancer-specific survival for all breast cancers, estrogen receptor (ER)-
positive and ER-negative breast cancers. HR hazard ratio, CI 95% confidence interval, FDR false discovery rate
Risk factor All ER-positive ER-negative
HR CI P value FDR HR CI P value FDR HR CI P value FDR
Alcohol consumption (drinks per week) 1.10 0.76–1.60 0.62 0.92 1.12 0.69–1.81 0.65 0.65 0.91 0.42–1.97 0.82 0.90
Body mass index (adult, kg/m2) 1.01 0.81–1.25 0.95 0.95 1.10 0.83–1.45 0.52 0.62 1.14 0.72–1.82 0.57 0.88
Height (adult, m) 0.99 0.89–1.11 0.89 0.95 1.04 0.91–1.21 0.55 0.62 1.08 0.82–1.27 0.88 0.90
Mammographic density (dense vs non-dense area) 0.94 0.75–1.18 0.59 0.92 0.90 0.75–1.08 0.24 0.59 1.12 0.79–1.60 0.52 0.88
Menarche (age at onset) 1.07 0.97–1.18 0.21 0.92 1.06 0.94–1.21 0.34 0.61 1.06 0.86–1.29 0.59 0.88
Menopause (age at onset) 1.01 0.98–1.05 0.49 0.92 1.03 0.98–1.08 0.21 0.59 1.01 0.93–1.08 0.90 0.90
Physical activity (overall physical activity time) 1.06 0.52–2.16 0.87 0.95 1.66 0.48–5.71 0.43 0.62 0.36 0.09–1.54 0.17 0.77
Smoking behaviour (ever vs never) 1.07 0.83–1.38 0.59 0.92 0.82 0.58–1.16 0.26 0.59 1.53 0.92–2.54 0.10 0.77
Type 2 diabetes mellitus (yes vs no) 1.10 1.04–1.18 0.01 0.02 1.09 1.01–1.18 0.04 0.32 1.09 0.97–1.24 0.15 0.88
Fig. 1 Effect of the nine breast cancer risk factors on breast cancer-specific survival in all breast cancers. The y-axis shows the −log10(P value)
effect for the association. The x-axis corresponds to log (hazard ratio) effect for each of the traits on breast cancer survival. The risk factors with
false discovery rate (FDR) < 0.05 are coloured in red; the size of the circle is proportional to the −log10(FDR)
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instrument (HR = 1.14, CI = 0.94–1.38, P = 0.174) was
also not significant.
Genetic association between T2DM and breast cancer-
specific survival
The HR estimate for T2DM and survival among all inva-
sive breast cancers (HR = 1.10) was higher than that for ei-
ther ER-subtype individually (ER-positive: HR = 1.09; ER-
negative: HR = 1.09). This reflected the fact that the pa-
tients without ER-status information (n = 13,557) had a
larger risk estimate (HR = 1.19, CI = 1.02–1.39, P = 0.023).
To further validate the association between T2DM and
breast cancer-specific survival, we performed the analysis
using a shorter follow-up. The results were significant and
similar to the main analysis both for 10-year (HR = 1.12,
CI = 1.05–1.19, P = 0.0006) and for 5-year follow-up (HR =
1.13, CI = 1.04–1.23, P = 0.005). We also tested the associ-
ation in a model adjusted by other known prognostic fac-
tors. The association of T2DM with breast cancer-specific
survival in the adjusted model was still significant (HR =
1.10, CI = 1.02–1.18, P = 0.013), and the effect size
remained similar to the main T2DM analysis (HR = 1.10,
CI = 1.04–1.18, P = 0.003). Finally, we tried to replicate the
result using another large and well-powered GWAS, i.e. the
T2DM summary estimates from the DIAGRAM GWAS
which is a large meta-analysis of 32 studies comprising data
for 898,130 individuals (74,124 T2DM cases and 824,006
controls) of European ancestry [46]. The genetic instrument
for this dataset included 152 SNPs (12 SNPs overlapping
with the T2DM genetic instrument we initially used,
Additional file 2: Table S11). The association of T2DM with
breast cancer-specific survival using the replication dataset
was significant (HR = 1.18, CI = 1.04–1.33, P = 0.009) and
similar to the initial result (HR = 1.10).
Association between T2DM and breast cancer-specific
survival with BMI adjustment
To explore the potential confounding effect of BMI with
T2DM, we performed an analysis adjusting for genetic-
ally predicted BMI. The effect of BMI in this analysis
was not significant (HR = 1.02, CI = 0.85–1.24, P =
0.809), and the effect of T2DM on survival was similar
(HR = 1.10, CI = 1.04–1.17, P = 0.002) to the main
T2DM analysis (HR = 1.10, CI = 1.04–1.18, P = 0.003).
Causal association between T2DM and breast cancer-
specific survival
We used different variations of the MR method to assess
possible violations of the MR assumptions. Figure 2
shows that the range of MR methods used (simple
Fig. 2 Plot showing the effect sizes of the SNP effects on breast cancer-specific survival for all breast cancers (y-axes) and the SNP effects on
T2DM (x-axes) with 95% confidence intervals. Each dot represents one of the 95 SNPs used in the T2DM genetic instrument. The slopes indicate
the estimate for each of the five different MR tests
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mode, weighted median, and weighted mode) to assess
the sensitivity of the findings all gave similar effect size
estimates. Additionally, there was no evidence of plei-
otropy based on the MR-Egger intercept test (MR-Egger
intercept = 0.003, P = 0.68, Fig. 2). In analyses using
funnel plot (Additional file 1: Figure S1) and a leave-
one-out test (Additional file 1: Figure S2), there was no
indication for violation of the assumptions, nor that the
association was driven by any particular SNP.
Discussion
We performed a Mendelian randomisation analysis to
explore the potential causal effects on breast cancer-
specific survival of nine established risk factors for breast
cancer: alcohol consumption, BMI, height, mammo-
graphic density, menarche, menopause, physical activity,
smoking, and T2DM. We used survival estimates from
86,627 European breast cancer patients with invasive
breast cancer (by far the largest such dataset) and sum-
mary data from the GWAS Catalog for the nine risk fac-
tors. We used the IVW method to estimate causal
effects and performed a wide range of sensitivity analyses
to test the robustness of our findings.
Our analysis showed an association between genetic li-
ability to T2DM and worse breast cancer-specific sur-
vival. The IVW method result was consistent with the
results of other complementary MR-methods, and the
performed sensitivity analyses did not give any statistical
indication for violations of the MR assumptions. Add-
itionally, the T2DM GWAS used was reasonably pow-
ered, with an estimated heritability of ~ 20% [32],
supporting the relevance assumption. There was no evi-
dence that the SNPs were associated with breast cancer
survival (exclusion restriction). Finally, the association
remained significant when adjusting for other known
prognostic factors and when shortening the follow-up
time to 10 and 5 years.
Because obesity and T2DM share some biological fea-
tures such as elevated insulin levels, hypertension, and
chronic inflammation [47] and since higher BMI has
been associated with increased incidence of T2DM [48],
we explored a possible interaction between the two risk
factors. First, we ensured that there were no common
SNPs between the T2DM and BMI genetic instruments
or SNPs in LD that could be driving the association. Sec-
ond, we performed BMI-adjusted analyses which also
showed that the association was being driven by T2DM
and not by BMI.
Earlier literature suggests an association between dia-
betes and worse breast cancer-specific survival [49–51].
There is no clear evidence linking diabetes to any par-
ticular ER-status specific breast cancer subtype [52] that
could explain the poorer survival in women with T2DM.
The increased mortality in patients with T2DM might
be explained by the effect of insulin resistance or hyper-
insulinemia, since breast cancer cells might have a se-
lective growth advantage because of insulin receptor
overexpression [53, 54]. However, to our knowledge, no
functional studies to evaluate this have yet been carried
out. An important point to consider when interpreting
the results is that, when using a binary risk factors such
as T2DM, the genetic instrument estimate will only
represent the average causal effect of the exposure in a
fraction of the studied population (named “genetic com-
pliers”). Additionally, the latter would only be true as-
suming that the monocity assumption is plausible, which
means that increasing number of alleles for an individual
would increase (or maintain constant) the risk of having
T2DM [55].
All the other risk factors gave null results. Some of
these may reflect the fact that there is no true associ-
ation, but others may be underpowered since the frac-
tion of variation of the risk factor explained by the
genetic instrument was too small. The heritability ex-
plained by identified SNPs, and hence the power of the
genetic instruments, varies substantially between risk
factors, e.g. ~ 20% for T2DM [32] versus only 1% for the
mammographic density GWAS [27]. In addition, we only
kept genome-wide significant SNPs and dropped all
SNPs in LD or with low imputation quality in the BCAC
dataset, so the explained variation that we could utilise
was smaller. As GWAS become larger and more power-
ful genetic instruments are available, it may be possible
to find associations that could not be identified here.
However, for those risk factors with a predicted small
genetic component (e.g. physical activity), their associ-
ation with breast cancer survival might not be
assessable using an MR framework [8]. A potential
limitation of our study is that some patients in the
breast cancer survival dataset were also included in
the GWASs for the risk factors, mammographic dens-
ity (~ 2.5% overlap) and age at menarche (~ 27%) and
menopause (~ 21%). However, because the genetic in-
struments of age at menarche and menopause were
relatively strong and there was little overlap for mam-
mographic density, we may expect the bias caused by
patient overlap to be small [56]. Finally, another po-
tential reason for which we did not observe associ-
ation for some risk factors might be due to selection
bias. This type of collider bias can lead to an under-
or overidentification of genetic risk factors for breast
cancer survival due to a relationship between the gen-
etic risk factor concerned and breast cancer incidence
[57]. This could be the case for BMI, age at meno-
pause and menarche, or height, which have been
causally associated with breast cancer risk [58]. For
other risk factors such as T2DM or smoking, MR
studies of incidence could not provide evidence for a
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causal association [59, 60], which makes these genetic
instruments less likely to be affected by selection bias.
To further explore the link between BMI and breast
cancer survival, we also tested separately for pre- and
postmenopausal status, but there was no indication for
an association in any of the menopausal groups. Despite
the evidence for an association between BMI and breast
cancer survival from observational studies [12, 13], our
analysis on BMI and breast cancer-specific survival did
not confirm this. A possible explanation is that obesity is
associated with other comorbid conditions [48] that lead
to poorer overall, but no breast cancer-specific survival.
Additionally, it has been suggested that obese patients
might receive suboptimal chemotherapy treatment com-
pared to regular weight women [61] and tumours are
usually detected at a later stage in obese patients [62].
This would, if insufficiently corrected for, lead to an as-
sociation between high BMI and worse breast cancer-
specific survival in observational, but not in MR, studies.
The different observations of the relationship between
BMI and survival from MR versus observational studies
resemble those of genetic BMI and breast cancer risk
[63], which were also deviant from epidemiological
studies. To date, there is not a clear answer as to
whether and how high BMI directly influences the
biology of cancer [64].
From a clinical point of view, our analysis suggests
that genetic liability to T2DM may contribute to vari-
ation in breast cancer outcomes in women of European
ancestry. Such a genetic predictor might be included in
prognostication models aimed at identifying women
most likely to benefit from specific interventions. Fur-
thermore, even though T2DM has a genetic component,
it is also influenced by environmental and lifestyle fac-
tors and is potentially preventable [65]. Although our
study does not address this directly, it seems sensible to
recommend intensified management of T2DM, includ-
ing lifestyle changes, in breast cancer patients.
The main strength of our study is the use of the
biggest breast cancer dataset available so far and the
use of SNPs as genetic instruments to reduce poten-
tial confounding. Despite including more than 7000
breast cancer-specific deaths in the analyses, our
study was not well powered especially for the analysis
within the subset of ER-negative tumours (as indi-
cated by the broad confidence intervals). Additional
findings might be possible when there are larger sam-
ple sizes available and a more complete follow-up.
We also lacked power to detect associations for cer-
tain risk factors that had only a handful of SNPs in
their genetic instruments such as mammographic
density and physical activity. Finally, our results are
applicable to women of European ancestry only. In
order to be able to generalise these findings to other
ancestry groups, larger breast cancer datasets are
needed for the other ethnicities.
Conclusion
This two-sample MR analysis suggests that genetic
liability to T2DM might be a cause of reduced breast
cancer-specific survival. Our study provides further evi-
dence for the importance of promoting a healthier life-
style to improve survival in breast cancer patients.
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